Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: October 24th 2024 | Updated: October 25th 2024
The Present and Future of Endocrine Therapy in Breast Cancer
Published: October 24th 2024 | Updated: October 25th 2024
Osimertinib: Evolution of Treatment from Refractory Disease to Prevention of Drivers of Disease Progression
Published: January 11th 2023 | Updated: October 25th 2024
IO/IO Versus IO/TKI Frontline Therapy for Intermediate-Risk RCC
Published: July 15th 2022 | Updated: October 25th 2024
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
Published: May 29th 2019 | Updated: October 25th 2024
FDA Grants Fast Track Designation to Lasofoxifene for ER+, ESR1-Mutant Metastatic Breast Cancer